Strategic partnerships Daiichi Sankyo actively engages in clinical collaborations with major players like Summit Therapeutics and AstraZeneca, presenting ongoing opportunities for co-development and co-commercialization in oncology and related therapies.

Therapy expansion The company focuses on cancer and cardiovascular areas with high unmet medical need, offering sales prospects for novel modalities such as Datroway and Enhertu, as well as potential ADC discovery and development partnerships.

Digital health Recent ventures into AI powered digital therapeutics (UNITE) and data driven patient support indicate upsell possibilities for digital companion products, remote monitoring, and adherence solutions in oncology care.

Commercial acceleration Appointment of a Chief Commercialisation Officer and the launch of a dedicated Commercialisation Unit signal a push to scale oncology and specialty medicine sales, creating collaboration opportunities with commercial analytics, market access, and field execution partners.

Legal and risk context Ongoing legal and enforcement activity involving related entities suggests a need for compliant, transparent partner due diligence and risk assessment when pursuing collaborations or supply arrangements in multiple jurisdictions.